Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

12 Health Care Stocks Moving In Thursday's Pre-Market Session

 

Gainers

  • NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5 million. The company's, Q1 earnings came out 3 days ago.
  • Biofrontera (NASDAQ:BFRA) stock rose 11.85% to $3.49. The market value of their outstanding shares is at $98.9 million.
  • Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 9.76% to $4.27. The company's market cap stands at $214.3 million.
  • Revelation Biosciences (NASDAQ:REVB) stock rose 9.41% to $2.44. The market value of their outstanding shares is at $34.7 million.
  • INmune Bio (NASDAQ:INMB) stock rose 9.38% to $12.0. The market value of their outstanding shares is at $214.1 million.
  • Rhythm Pharmaceuticals (NASDAQ:RYTM) stock moved upwards by 7.08% to $7.1. The market value of their outstanding shares is at $356.9 million.

Losers

  • 10x Genomics (NASDAQ:TXG) stock decreased by 23.7% to $72.5 during Thursday's pre-market session. The market value of their outstanding shares is at $8.0 billion. As per the news, the Q4 earnings report came out yesterday.
  • Marker Therapeutics (NASDAQ:MRKR) shares fell 19.03% to $0.5. The company's market cap stands at $41.5 million. The company's, Q4 earnings came out yesterday.
  • Larimar Therapeutics (NASDAQ:LRMR) stock fell 7.11% to $3.66. The market value of their outstanding shares is at $64.8 million.
  • Dermata Therapeutics (NASDAQ:DRMA) stock fell 6.35% to $1.18. The market value of their outstanding shares is at $9.8 million.
  • Orphazyme (NASDAQ:ORPH) stock fell 5.01% to $2.09. The market value of their outstanding shares is at $73.0 million.
  • Biolase (NASDAQ:BIOL) stock fell 4.45% to $0.39. The market value of their outstanding shares is at $60.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.